1.	PF-00299804 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Standard Therapy for Advanced or Metastatic Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Health services research, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: BR26, CAN-NCIC-BR26, PFIZER-CAN-NCIC-BR26, CDR0000657246, NCT01000025
2.	ARCHER 1009 : A Study Of PF-00299804 (Dacomitinib) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A7471009, NCT01360554
3.	Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WS590266, NCT01116843
4.	PF-00299804 As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A7471017, NCT00818441
5.	PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 90 Sponsor: Other Protocol IDs: 09-468, WS573383, NCT01112527
6.	PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: H-1004-031-315, NCT01152853
7.	PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 4-2011-0434, NCT01449201
8.	Study Of Dacomitinib In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO Phase: Phase II Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A7471042, NCT01465802
9.	Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II Clinical Trial. Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GEINO 11, NCT01520870
10.	A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: 4-2012-0014, NCT01608022
11.	A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of PF-00299804 in Patients With Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A7471001, UCLA-0506123-01, PFIZER-A7471001, NCT00225121
12.	A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A8081006, NCT01121575
13.	-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110250, 11-C-0250, NCT01441128
14.	A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WS1544542/Pan-HER-GT-001, NCT01484847